Law360, New York (May 04, 2011, 10:58 PM ET) -- Flamel Technologies SA filed a patent infringement suit against Lupin Ltd. in Washington on Wednesday over the Indian drug manufacturer's abbreviated new drug application for a generic version of heart-failure treatment drug Coreg.
A generic version of the drug would infringe on U.S. Patent No. 6,022,562, which is held by Flamel and associated with Coreg, according to a press release from Flamel.
The '562 patent, called "Medicinal and/or nutritional microcapsules for oral administration," covers a process for the production of microcapsules and a description of the...
Flamel Takes Lupin To Court Over Generic Coreg
To view the full article, take a free trial now.
